| Patient | Higuchi Ichiyō |
|---|---|
| Date of birth | 1872-05-02 |
| Identifiers | MRN HR-NI029-SYN-TD; SSN (made up) 000-29-5108 |
| Document date | 1896-10-20 |
| Author | Aiko Lindgren-Tanaka, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
End-of-treatment review after six months. [S]
Ms. Higuchi returns having completed treatment five days ago: all 182 doses were observed by video, 56 in the intensive phase and 126 in the continuation phase, with none missed. The two-month sputum culture showed no growth. She has had no cough, fever or night sweats for four months and has gained 5.5 kg since intake. She has had no nausea, yellowing, numbness or change in vision. The cystitis in the summer did not return. The public health center has told her that its contact investigation is complete. She writes each morning and has finished two stories since the summer. Her cervical cytology was normal. [S]
| Element | Detail |
|---|---|
| Treatment | 182 of 182 doses observed; completed five days ago |
| Bacteriology | Two-week and two-month cultures negative |
| Weight | 44.0 kg, up 5.5 kg from intake |
| Writing | Two new stories finished |
| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No cough, sputum or breathlessness |
| Constitutional | Negative | No fever, night sweats or weight loss |
| Gastrointestinal | Negative | No nausea or jaundice |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Mood good; PHQ-9 3 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Isoniazid 100 mg tablets, two tablets (200 mg) daily | 200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily | 450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phase | Oral route | 1896-04-17 to 1896-06-11 | completed | S |
| Ethambutol 100 mg tablets, six tablets (600 mg) daily | 600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results return | Oral route | 1896-04-17 to 1896-05-22 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Nitrofurantoin monohydrate/macrocrystals 100 mg oral capsule, one capsule twice daily with food for five days | One capsule twice daily with food for five days | Oral route | 1896-07-20 to 1896-07-24 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1896-10-20 | Body height | 148 | cm | S |
| 1896-10-20 | Body weight | 44 | kg | S |
| 1896-10-20 | Body mass index (BMI) [Ratio] | 20.1 | kg/m2 | S |
| 1896-10-20 | Systolic blood pressure | 106 | mm[Hg] | S |
| 1896-10-20 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1896-10-20 | Heart rate | 72 | /min | S |
| 1896-10-20 | Respiratory rate | 14 | /min | S |
| 1896-10-20 | Body temperature | 36.5 | Cel | S |
| 1896-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1896-10-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-35 U/L | Normal | S |
| 1896-10-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 10-35 U/L | Normal | S |
| 1896-10-20 | Albumin [Mass/volume] in Serum or Plasma | 4.2 | g/dL | 3.5-5 g/dL | Normal | S |
| 1896-10-20 | Hemoglobin [Mass/volume] in Blood | 13.2 | g/dL | 12-15.5 g/dL | Normal | S |
| 1896-10-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 1896-10-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 44.0 kg, BMI 20.1; temperature 36.5 °C, pulse 72, blood pressure 106/68 |
| Eyes | No icterus |
| Respiratory | Clear on both sides |
| Abdomen | Soft; liver not enlarged |
| Neurological | Normal sensation and reflexes in the feet |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and culture | resolved | confirmed | R05.3 | S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D). |
| Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected) | resolved | confirmed | A15.0 | S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic. |
| Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dL | resolved | confirmed | E44.0 | S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty. |
| Low and irregular income from writing, with a household to support; costs of care are a barrier | active | confirmed | Z59.6 | S — Synthetic social need anchored to her documented poverty and household responsibilities. |
| Acute uncomplicated cystitis, treated with nitrofurantoin rather than a fluoroquinolone during tuberculosis treatment; resolved | resolved | confirmed | N30.00 | S — Synthetic intercurrent illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, fever, night sweats | At least monthly during treatment | Completed today | No symptoms for four months |
| Self-management | Weight and nutrition | Every visit; dose review if weight changes by more than about 5 kg | Completed today | 44.0 kg, BMI 20.1; albumin 4.2 g/dL |
| Medication safety | Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine) | Every visit and every observed dose | Completed today | No symptoms throughout the continuation phase |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptoms | Completed today | ALT 18, AST 20 U/L at the end of treatment; no tests were needed for symptoms in the continuation phase |
| Laboratory | Two-month sputum smear and culture | At the end of the intensive phase | Completed today | Smear negative; no growth at six weeks, as with the two-week culture |
| Laboratory | Blood count | At diagnosis, then as needed | Completed today | Hemoglobin 13.2 g/dL, normal |
| Imaging | Chest X-ray | At diagnosis and at the end of treatment as a new baseline | Completed today | Opacities cleared, with a few linear scars; new baseline |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | 182 of 182 doses observed; treatment completed |
| Medication safety | Peripheral neuropathy check, with pyridoxine | Every visit | Completed today | No neuropathy; pyridoxine stopped with isoniazid |
| Imaging | Visual acuity and color vision | Baseline and monthly while on ethambutol | Not indicated | Ethambutol stopped in the fifth week; acuity normal at two months |
| Referral | Contact investigation (household and close contacts) | Led by the public health center, from diagnosis | Completed today | The public health center reports the investigation complete; results are held in the contacts' own records |
| Referral | Report of treatment outcome to the public health center | At the end of treatment | Completed today | Treatment completed reported |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Completed today | PHQ-9 3, item 9 scored 0 |
| Self-management | Hepatitis B, HPV and influenza vaccines | Hepatitis B in two doses four weeks or more apart; HPV in three doses; influenza each autumn | Completed today | Hepatitis B dose 2 (series complete), HPV dose 2 and influenza vaccine given today; HPV dose 3 due in four months |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Human papillomavirus 9-valent vaccine, dose 2 of 3; Influenza vaccine, inactivated, trivalent, preservative-free [S]
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025); WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); 結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law (current); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012); Depression and Suicide Risk in Adults: Screening (2023); Adult Immunization Schedule by Age (2026)
Follow-up: No routine tuberculosis follow-up; return for symptoms. HPV dose 3 in four months. Next preventive visit in about ten months. [S]